| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8218717 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
Sunitinib at a daily dose of 37.5Â mg given concurrently with hypofractionated stereotactic reirradiation for rHGG yields acceptable toxicities and an encouraging 6-month progression-free survival.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Evan J. MD, Walter J. MD, Kevin MD, Alexander MD, Jon MD, James MD, David W. MD, Rita MD, Wenyin MD, PhD, Maria MD, E. Mark PhD, Gilda G. PhD, Adam P. MD, PhD,